Disappointing Results for Perifosine

Perifosine was no better than a placebo in improving survival time for people with late-stage colorectal cancer according to a news release from Keryx Biopharmaceuticals. Despite success in a smaller Phase II clinical trial, the X-PECT Phase III trial failed to meet its primary objective — longer survival time. X-PECT randomized 468 patients to receive either:…  Read More

X-PECT Trial is Fully Enrolled

The X-PECT phase III clinical trial has finished recruiting over 430 patients, evaluating perifosine treatment for patients with advanced colorectal cancer who have exhausted standard treatments. The trial compares the effectiveness of adding perifosine to Xeloda® (capecitabine). Led by Johanna Bendell, M.D., from the Sarah Cannon Research Institute in Nashville, TN, the trial is being conducted…  Read More